Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

(2020) Sabina Chiaretti et al.   BLOOD

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

(2020) Liora M Schultz et al.   BLOOD

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

(2020) Norman J. Lacayo et al.   BLOOD

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

(2020) Anjali S. Advani et al.   BLOOD

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

(2020) Nicholas J. Short et al.   BLOOD

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party

(2020) Eolia Brissot et al.   BONE MARROW TRANSPLANTATION

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).

(2020) Xinxin Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study

(2020) Ying-Jun Chang et al.   Journal of Hematology & Oncology

Acute lymphoblastic leukaemia

(2020) Florent Malard et al.   LANCET

Allogeneic CAR T cell therapies for leukemia - R1

(2019) Waseem Qasim   AMERICAN JOURNAL OF HEMATOLOGY

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

(2019) Wendy Stock et al.   BLOOD

Acute Lymphoblastic Leukemia in the Older Adult

(2019) Ibrahim Aldoss et al.   Journal of Oncology Practice

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

(2019) Juanjuan Zhao et al.   Journal of Hematology & Oncology

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

(2019) Delong Liu et al.   Journal of Hematology & Oncology

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

(2019) Hagop M. Kantarjian et al.   CANCER

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances

(2019) Irene Della Starza et al.   Frontiers in Oncology

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival

(2019) Musa Yilmaz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

(2019) Persis J Amrolia et al.   BLOOD

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

(2019) Guillaume Richard-Carpentier et al.   BLOOD

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

(2019) Nitin Jain et al.   BLOOD

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

(2019) Koji Sasaki et al.   BLOOD

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

(2019) Bachar Samra et al.   BLOOD

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

(2018) Karen L. Bride et al.   BLOOD

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

(2018) Nicola Gökbuget et al.   BLOOD

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia

(2018) Elias Jabbour et al.   Clinical Lymphoma Myeloma & Leukemia

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

(2018) Sang-Kyu Kim et al.   GENES & DEVELOPMENT

Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia

(2018) Chezi Ganzel et al.   HAEMATOLOGICA

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

(2018) Hagop Kantarjian et al.   LANCET ONCOLOGY

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

(2018) Matthew L Cooper et al.   LEUKEMIA

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

(2018) Nicholas J. Short et al.   Current Hematologic Malignancy Reports

Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia

(2018) Chezi Ganzel et al.   HAEMATOLOGICA

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

(2018) Elias Jabbour et al.   JAMA Oncology

Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia

(2018) Elias Jabbour et al.   JAMA Oncology

COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.

(2018) Kimberly P. Dunsmore et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.

(2018) Abdul Hamid Bazarbachi et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

(2018) Elias Jabbour et al.   JOURNAL OF CLINICAL ONCOLOGY

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease

(2018) Katherine C. Pehlivan et al.   Current Hematologic Malignancy Reports

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

(2018) Nicholas J. Short et al.   AMERICAN JOURNAL OF HEMATOLOGY

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

(2018) Sebastian Giebel et al.   BONE MARROW TRANSPLANTATION

Early Response–Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study

(2017) Jonathan Bond et al.   JOURNAL OF CLINICAL ONCOLOGY

High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults

(2017) Kathryn G. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

(2017) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia

(2017) N Toft et al.   LEUKEMIA

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

(2017) J Duell et al.   LEUKEMIA

Managing CNS disease in adults with acute lymphoblastic leukemia

(2017) Richard A. Larson   LEUKEMIA & LYMPHOMA

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT

(2017) Gabrielle Roth-Guepin et al.   Oncotarget

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

(2017) Donald A. Berry et al.   JAMA Oncology

Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia

(2016) Ashley E. Rosko et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

(2016) Nitin Jain et al.   BLOOD

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2016) N. J. Short et al.   BLOOD

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

(2016) Philippe Rousselot et al.   BLOOD

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

(2016) N. Jain et al.   BLOOD

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

(2016) Ghayas C. Issa et al.   CANCER

Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the

(2016) Sebastian Giebel et al.   CANCER

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

(2016) Koji Sasaki et al.   CANCER

Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study

(2016) Y. Wang et al.   CLINICAL CANCER RESEARCH

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

(2016) N. Gokbuget et al.   HAEMATOLOGICA

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy

(2016) Ajay Vora et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

(2016) Sébastien Maury et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

(2016) N. Gokbuget et al.   HAEMATOLOGICA

Ph-like acute lymphoblastic leukemia

(2016) T. H. Tran et al.   Hematology-American Society of Hematology Education Program

Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia

(2015) D.-Y. Kim et al.   BLOOD

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

(2015) Y. Chalandon et al.   BLOOD

Monoclonal antibodies in acute lymphoblastic leukemia

(2015) E. Jabbour et al.   BLOOD

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

(2015) N. Dhedin et al.   BLOOD

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

(2015) Farhad Ravandi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003

(2015) Rachael Hough et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) Farhad Ravandi et al.   CANCER

BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells

(2015) S. E. Alford et al.   CANCER RESEARCH

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) N. Daver et al.   HAEMATOLOGICA

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

(2015) Elias Jabbour et al.   LANCET ONCOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) N. Daver et al.   HAEMATOLOGICA

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

(2015) Kathryn G. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Chimerism and Minimal Residual Disease Monitoring for Relapse Prediction after Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia

(2014) Theis Helge Terwey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

(2014) D. Hoelzer et al.   BLOOD

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

(2014) K. Beldjord et al.   BLOOD

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002

(2014) David A. Rizzieri et al.   BRITISH JOURNAL OF HAEMATOLOGY

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

(2014) Michael E. Rytting et al.   CANCER

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

(2014) Josep-Maria Ribera et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia

(2014) D J DeAngelo et al.   LEUKEMIA

Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group

(2014) F Hayakawa et al.   Blood Cancer Journal

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

(2014) T. N. Chonghaile et al.   Cancer Discovery

Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations

(2013) M. Neumann et al.   BLOOD

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

(2013) A. K. Fielding et al.   BLOOD

How I treat older patients with ALL

(2013) N. Gokbuget   BLOOD

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

(2013) Hagop Kantarjian et al.   CANCER

Toward a NOTCH1/FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study

(2013) Amélie Trinquand et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

(2012) Aline Tanguy-Schmidt et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

(2012) N. Gokbuget et al.   BLOOD

Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

(2012) Kimberly P. Dunsmore et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

(2012) Andrea Biondi et al.   LANCET ONCOLOGY

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

(2012) H Pfeifer et al.   LEUKEMIA

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

(2012) Jinghui Zhang et al.   NATURE

Anti-CD20 Antibody Therapy for B-Cell Lymphomas

(2012) David G. Maloney   NEW ENGLAND JOURNAL OF MEDICINE

Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia

(2012) Huimin Geng et al.   Cancer Discovery

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation

(2011) Xiao-Su Zhao et al.   ANNALS OF HEMATOLOGY

High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation

(2011) N. Gokbuget et al.   BLOOD

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2011) R. Foa et al.   BLOOD

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

(2010) F. Ravandi et al.   BLOOD

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

(2010) Deborah A. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

(2009) A. V. Moorman et al.   BLOOD

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

(2009) D. I. Marks et al.   BLOOD

Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL

(2009) S Giebel et al.   BONE MARROW TRANSPLANTATION

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen

(2009) John M. Storring et al.   BRITISH JOURNAL OF HAEMATOLOGY

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993

(2009) Bella Patel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

(2009) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

(2009) Elaine Coustan-Smith et al.   LANCET ONCOLOGY

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

(2009) Monique L Den Boer et al.   LANCET ONCOLOGY

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

(2008) Susan O'Brien et al.   CANCER

Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

(2008) Josep-María Ribera et al.   JOURNAL OF CLINICAL ONCOLOGY

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-LALA group

(2008) Oumedaly Reman et al.   LEUKEMIA RESEARCH

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

(2008) Charles G. Mullighan et al.   NATURE